Skip to main content

REVIEW article

Front. Oncol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1481777
This article is part of the Research Topic The Molecular Mechanism in Anti-tumor Therapy Resistance View all 9 articles

Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer

Provisionally accepted
Zhe Zhu Zhe Zhu 1Wenjing Xuan Wenjing Xuan 1Chaohui Wang Chaohui Wang 2Chancan Li Chancan Li 1*
  • 1 Anhui No 2 Provincial People's Hospital, Hefei, Anhui Province, China
  • 2 Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, China

The final, formatted version of the article will be published soon.

    Prostate cancer is a malignant tumor caused by the malignant proliferation of epithelial cells, which is highly heterogeneous and drug-resistant, and neuroendocrine prostate cancer (NEPC) is an essential cause of drug resistance in its late stage. Elucidating the evolution of NEPC and the resistance process of enzalutamide, a novel antiandrogen, will be of great help in improving the prognosis of patients. As a research hotspot in the field of molecular biology in recent years, the wide range of biological functions of long noncoding RNAs (lncRNAs) has demonstrated their position in the therapeutic process of many diseases, and a large number of studies have revealed their critical roles in tumor progression and drug resistance. Therefore, elucidating the involvement of lncRNAs in the formation of NEPCs and their interrelationship with enzalutamide resistance may provide new ideas for a deeper understanding of the development of this disease and the occurrence of enzalutamide resistance and give a new direction for reversing the therapeutic dilemma of advanced prostate cancer. This article focuses on lncRNAs that regulate enzalutamide resistance and the neuroendocrine transition of prostate cancer through epigenetic, androgen receptor (AR) signaling, and non-AR pathways that act as "molecular sponges" interacting with miRNAs. Some insights into these mechanisms are used to provide some help for subsequent research in this area.

    Keywords: long noncoding RNA, enzalutamide, enzalutamide resistance, neuroendocrine prostate cancer, AR, prostate cancer

    Received: 16 Aug 2024; Accepted: 08 Nov 2024.

    Copyright: © 2024 Zhu, Xuan, Wang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Chancan Li, Anhui No 2 Provincial People's Hospital, Hefei, Anhui Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.